uniQure N.V. (QURE), a gene therapy company, announced Monday that the company received final meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a Type A meeting held on January 30, 2026 to discuss AMT-130, an investigational gene therapy for Huntington's disease (HD).
The FDA stated that it cannot agree that data from the Phase I/II studies, compared to an external control, are sufficient to provide the primary evidence of effectiveness required to support a marketing application for AMT-130.
The FDA strongly recommended uniQure conduct a prospective, randomized, double-blind, sham surgery-controlled study.
uniQure intends to continue engaging with the FDA regarding Phase III development considerations and plans to request a Type B meeting in the second quarter of 2026 to further discuss potential study design approaches.
"We remain committed to engaging with the FDA to determine a clear, scientifically grounded, and efficient path forward for AMT-130," said Matt Kapusta, chief executive officer at uniQure.
In Monday's pre-market trading, QURE is trading on the Nasdaq at $9.10, down $6.53 or 41.77 percent.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.